Introduction {#sec1-1}
============

It is well-documented that insulin resistance is one of the major pathophysiology of type 2 diabetes. Thiazolidinedione (TZD), a category of antidiabetic medication, can regulate genes expression to improve insulin sensitivity through binding with the peroxisome proliferation activation receptor -- γ (PPAR-γ).\[[@ref1]\] It was regarded as the only treatment to improve insulin resistance in type 2 diabetes. Unfortunately, the first generation, troglitazone, was withdrawn 3 years later due to episodes of severe liver injury.\[[@ref1]\] The second-generation rosiglitazone and pioglitazone were then launched in 1999. The postmarketing studies showed no increased risk of hepatotoxicity with these drugs.\[[@ref2]\] Sporadic case reports of acute hepatitis, including one death, which may be attributed to rosiglitazone, although alternative causes cannot be entirely excluded in these cases.\[[@ref3]--[@ref7]\] Thus, the United States Food and Drug Administration suggested that rosiglitazone should not be initiated in patients with active liver disease or moderate-to-severe liver function impairment. Nonetheless, in some clinical trials, rosiglitazone and pioglitazone were found not to be associated with increased abnormalities of liver function.\[[@ref8]\] On the contrary, some studies even showed a substantial number of patients with non-alcoholic steatohepatitis (NASH), a disease related with insulin resistance, who had improved steatosis, inflammation, and liver fibrosis after administration of TZD.\[[@ref2][@ref9][@ref10]\] These findings, therefore, suggest the potential role of TZD in the treatment of patients of type 2 diabetes with NASH.

Although there are a large number of studies on the role of rosiglitazone in hepatitis, controversies exist. This is an open-labeled, 2-arm study designed to evaluate the effect of rosiglitazone in type 2 diabetes with normal and abnormal liver function at the baseline.

Materials and Methods {#sec1-2}
=====================

 {#sec2-1}

### Subjects and study design {#sec3-1}

Seventy-three patients with type 2 diabetes mellitus, diagnosed for more than six months from the outpatient clinic, were enrolled. Other inclusion criteria were age between 50 and 70 years and body mass index (BMI) 23-30 kg/m.^2^ Subjects with significant comorbidities, such as congestive heart failure, significant peripheral edema, chronic renal failure, peripheral arterial occlusive disease, decompensated liver cirrhosis or those taking medication that might affect the liver function were excluded. Subjects with a history of alcoholism and either hepatitis B or C were also excluded. The study was approved by the hospital\'s institutional review board and ethics committee and all subjects provided written informed consent prior to participation.

After 10 hours of fasting, the subjects visited the clinic and underwent complete physical examination. The BMI was calculated as body weight/height\[[@ref2]\] (kg/m^2^), while systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured on the right arm of seated subjects using standard mercury sphygmomanometer. Blood samples were drawn from the antecubital vein for biochemical analysis. Patients were divided into two groups based on their initial liver function tests: those with both normal serum aspartate aminotransferase (AST, reference ranges £ 40 U/L) and alanine aminotransferase (ALT, reference range £ 40 U/L) levels were defined as normal liver function group (NLF, *n*=42), \\ while, subjects with either elevated serum ALT (\>40 U/L) or AST (\>40 U/L) levels were defined as abnormal liver function group (ABLF, *n*=31).

These patients were treated with glibenclamide and/or metformin and the doses were maintained throughout the study period. Other medications such as antihypertensive or lipid-lowering agents were maintained. The patients were prescribed rosiglitazone 4mg daily for 3 months. They were instructed to continue their previous lifestyle, including diet and exercise throughout the study period. The blood biochemistries were examined at monthly intervals.

### Laboratory measurements {#sec3-2}

Plasma was separated from blood within one hour and stored at -30°C. Fasting plasma glucose (FPG) was determined using the glucose oxidase method (YSI 203glucose analyzer, Scientific Division, Yellow Spring Instrument Company, Inc., Yellow Spring, OH). Both triglyceride (TG) and total cholesterol (TC) levels were measured using the dry, multilayer analytical slide method (Fuji Dri-Chem 3000 analyzer, Fuji Photo Film Corporation, Minato-Ku, Tokyo, Japan). Serum high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) concentrations were determined using an enzymatic assay following dextran sulfate precipitation, while the level of hemoglobin A1c (HbA1c) was evaluated by the ion-exchange high-pressure liquid chromatography method (Variant II; Bio-Rad, Hercules, CA). Serum levels of both AST and ALT were measured using the kinetic rate method (Synchron LX System).

### Statistical analysis {#sec3-3}

Data were tested for normal distribution using the Kolmogorov-Smirnov test and for homogeneity of variances by Levene\'s test. Continuous variables were expressed as mean ± standard deviation. Independent *t*-test was used to evaluate liver function between the two groups. Paired *t*-test was used to assess the alterations of liver function of subjects in the two groups before and after rosiglitazone treatment. All statistical data were two-sided and a *P* value \<0.05 was considered to be statistically significant. All analyses were performed using the SPSS statistical package (version 16.0) for Windows (SPSS, Chicago, IL).

Results {#sec1-3}
=======

The baseline demographic characteristics of subjects in the NLF and ABLF groups are shown in [Table 1](#T1){ref-type="table"}. Subjects in the NLF group were older than those in the ABLF group. BMI, FPG, HbA1c, and lipid profiles were not significantly different between the two groups, except for higher levels of baseline liver function in the ABLF group.

###### 

The clinical and biochemical characteristics of the patients at baseline
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Glycemic control and lipids changes before and after 3 months of rosiglitazone treatment in the NLF and ABLF groups are presented in [Table 2](#T2){ref-type="table"}. Both FPG and HbA1c were lowered after the treatment with rosiglitazone. However, only the differences of FPG in the NLF group (*P*=0.002) and HbA1c in the ABLF group (*P*=0.027) reached statistical significance. AST and ALT decreased significantly in the ABLF group, while in the NLF group, only mild, nonsignificant decreases were noted. As for the lipids levels, there were no significant differences before and after treatment.

###### 

Glycemic control and lipids of the patients with normal and abnormal liver function at baseline and after 3 months of rosiglitazone treatment
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Monthly AST and ALT changes in the two groups are shown in Figures [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}, respectively. In comparison with the baseline, serum concentrations of both AST and ALT in the ABLF group decreased significantly at the end of the third month of treatment (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, *P*=0.006; ALT: 66.6 ± 35.0 to 51.9 ± 23.5 U/L, *P*=0.004, respectively). In the NLF group, the monthly concentrations of AST and ALT showed no significant difference. The incidence of hepatic injury in each group was also assessed. After 3 months of treatment, 21 out of 31 (67.7%) patients in the ABLF group had either abnormal ALT or AST levels while 2 out of 42 (4.8%) patients in the NLF group had abnormal ALT or AST levels.

![The changes of aspartate aminotransferase (AST, panel A) and alanine aminotransferase (ALT, panel B) after 3-month treatment with rosiglitazone in the normal liver function (NLF) and abnormal liver function (ABLF) groups. The data is shown as mean ± standard error. \**P*\<0.05 as compared with baseline](IJPharm-44-372-g003){#F1}

Since *ad hoc* sample size estimation was not conducted, *post hoc* power analysis of the AST and ALT levels was performed using the formula proposed by Dupont *et al*.\[[@ref11]\] In this study, the differences in AST and ALT were 10.25 and 14.67 and their corresponding standard deviations were 21.32 and 30.06, respectively. Under the presupposition of two-tailed significance, the estimated power of the differences in AST and ALT would be 0.73 and 0.74, respectively.

Discussion {#sec1-4}
==========

At present, pioglitazone and rosiglitazone are widely used in the clinical setting. In comparison to their predecessor, troglitazone, they are believed to be safer and not to be associated with a higher risk of hepatotoxicity. Lebovitz *et al*. found that in 22 studies and more than 6,000 patients, rosiglitazone did not show any hepatotoxic effects.\[[@ref12]\] In another study done in Taiwan, Wang *et al*. observed that around 30% of type 2 diabetic patients with elevated AST and/or ALT had an improvement in the liver enzymes. However, the cohort was small and there was no control group.\[[@ref10]\] In the present study, we investigated the changes of serum ALT and AST after 3 months of rosiglitazone treatment in diabetic Chinese population. Compared to the baseline, both serum ALT and AST concentrations decreased significantly at the end of treatment in the ABLF group, while there was no similar change in the NLF group \[[Figure 1](#F1){ref-type="fig"}\]. It should be stressed that although the results are not surprising and similar studies were done, our study is still the first one to have a control group (NLF group) which further confirmed that rosiglitazone does not increase liver enzymes, but could reduce them.

The mechanism of TZD in the improvement of liver function in diabetic patients remains unclear. However, two mechanisms might be involved; first, decreased insulin resistance and, second, the anti-inflammatory effect of TZD. Nowadays, more and more studies demonstrate that there is a strong association between obesity, insulin resistance and inflammatory mediators.\[[@ref13]--[@ref15]\] These inflammatory mediators play an important role in the development of NASH.\[[@ref16][@ref17]\] For instance, the plasma tumor necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) are increased in insulin resistant states. Consequently, high levels of these inflammatory markers, mostly seen in obese people and type 2 diabetes, might further interfere with insulin action by suppressing the insulin signal transduction.\[[@ref18]\] Through activation of PPAR-γ, a nuclear transcription factor, rosiglitazone increases insulin sensitivity, which not only inhibits lipolysis and decreases free fatty acid release but also facilitates free fatty acid uptake and triglyceride accumulation in the muscle, and consequently inhibits the inflammatory response of hepatocyte to dietary lipid overload.\[[@ref17][@ref19]\] In addition, rosiglitazone also promotes the uptake and storage of free fatty acid in adipocytes and facilitates the redistribution of fat from liver to peripheral adipocytes, which not only decreases insulin resistance since peripheral fat is less insulin resistant, but also reduces the liver steatosis and concurrent hepatic cell injury.\[[@ref20]\]

In addition to the effect of increased insulin sensitivity, some studies also showed that rosiglitazone could directly suppress inflammatory mediators, such as IL-6, interleukin-1β, resistin, and TNF-α.\[[@ref21]--[@ref24]\] Hong *et al*. reported that rosiglitazone could directly inhibit the secretion of TNF-a from primary human monocytes.\[[@ref21]\] Similarly, Tahan *et al*. demonstrated that rosiglitazone affected cytokines, including interleukin-6, interleukin-1β and TNF-α, which led to improved inflammation in NASH.\[[@ref22]\] Further, some studies reported that rosiglitazone exerted the anti-inflammatory effect through regulating some pathways such as NF-κB.\[[@ref25]--[@ref28]\] In addition to the direct anti-inflammatory effect, the decrease in inflammatory cytokines also increase insulin sensitivity, which can further diminish the liver inflammation. These anti-inflammatory effects through different mechanisms attenuate the inflammation of hepatocytes and finally lead to the improvement of liver function.

In comparison with the results observed in the ABLF group, there were no significant changes of liver function in the NLF group during the 3 months follow-up period in our study. The different findings may be attributed to an initial lower BMI, higher insulin sensitivity and lower inflammatory mediators in the NLF than those in the ABLF group.

The strength of our study is that we could compare the effect of rosiglitazone on the NLF and ABLF groups at the same time. However, there are several limitations in our study. First, only serum ALT and AST were evaluated. One may argue that these two liver markers are not accurate for evaluating liver function. However, since they are routine laboratory tests in primary health settings, our study provides information that may prove practical for clinicians. Also, ALT and AST reflect the acute hepatocellular damage, hence may predict acute liver injury after short-term use of rosiglitazone. Although we do not have data of other liver functions, we believe that these findings are useful. Further evaluation of liver function with abdominal sonogram, liver biopsy and other markers such as alkaline phosphate, γ-glutamyl transpeptidase, albumin, bilirubin, prothrombin time will further confirm our results. The short duration of the study and a small study population were other limitations. Further investigation with a larger population and longer follow-up period is warranted.

In conclusion, after 3-month rosiglitazone treatment in type 2 diabetes with elevated liver enzymes, significant improvement of ALT and AST levels were observed in this study. Although our results provides some evidence that rosiglitazone might not be contraindicated in diabetes with abnormal liver function as previously thought, further studies are needed to evaluate whether rosiglitazone is beneficial for diabetic patients with elevated liver enzymes.
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